Comments

• Unable to assess impact of “snorting drugs” addition to the question because of short follow-up time since implementation

• No indication of incident or prevalent HBV or HCV infection

• Two donors HIV + at follow-up donation; relationship to TAP risk is unknown

Previous slide

Next slide

Back to first slide

View graphic version